Scratching out the Epidermal Growth Factor Receptor Inhibitor Rash with a Multimodality Algorithm

2.50
Hdl Handle:
http://hdl.handle.net/10755/164933
Category:
Abstract
Type:
Presentation
Title:
Scratching out the Epidermal Growth Factor Receptor Inhibitor Rash with a Multimodality Algorithm
Author(s):
Camp, Kimberly; Rowe, Krista; Houchin, Laura; Waters, Mark; Barbour-Yowell, Sally; Tenhover, Jennifer; Leigh, Howard
Author Details:
Kimberly Camp, RN, BSN, OCN, Clinical Operations Director, Duke University Hospital, Durham, North Carolina, USA, email: camp0008@mc.duke.edu; Krista Rowe, MSN, CNS, AOCN; Laura Houchin, MSN, CNS, AOCN; Mark Waters, RN, MPH, OCN; Sally Barbour-Yowell, PharmD, BCOP; Jennifer Tenhover, ANP, AOCN; and Howard Leigh, FNP-BC
Abstract:
Clinical/Evidence Based Practice: Outpatient chemotherapy has progressed to a combination of targeted and cytotoxic therapies. Increased dermatological toxicities related to targeted therapies spearheaded the development of an algorithm for the management of epidermal growth factor receptor (EGFR) rashes. It is estimated that more than 50% of patients develop a mild to severe rash over the trunk, scalp, face and upper extremities. Skin toxicities can lead to dose reductions and/or dose delays along with decreased quality of life (QOL). Patients may report significant pain and pruritus, anxiety related to body image changes, and socially isolate themselves due to the appearance of the rash. Approximately 32% of providers report discontinuing therapy due to rash. The purpose of this project was to bring together a multidisciplinary group who could develop a clinical algorithm to guide patient care that would assist in minimizing dose delays/reductions and the negative impact on the patient's QOL. A multidisciplinary team was brought together that conducted a literature review and collaborated on the development of a skin toxicity algorithm. Development of the algorithm was accomplished by nurse practitioners, pharmacists and nurses who were identified as key change agents within oncology. A patient educational tool was also developed to compliment the algorithm which reinforces self-care symptom management strategies for good skin health. The algorithm is currently under review by the medical director, division chief, and the pharmacy and therapeutics committee for approval. Once the algorithm has been approved it will be disseminated to the staff in the clinics, infusion center, and pharmacy. Education and implementation of the algorithm and patient education materials is expected by March 2009. Helping patients maintain their QOL by minimizing symptoms and teaching self-care strategies can assist in avoiding delays and dose reductions of recommended cancer therapies. A standardized and consistent regimen for managing skin toxicities will minimize progression and severity of the rash allowing optimal treatment and minimizing the negative cosmetic impact of therapy.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2009
Conference Name:
34th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
San Antonio, Texas, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleScratching out the Epidermal Growth Factor Receptor Inhibitor Rash with a Multimodality Algorithmen_GB
dc.contributor.authorCamp, Kimberlyen_US
dc.contributor.authorRowe, Kristaen_US
dc.contributor.authorHouchin, Lauraen_US
dc.contributor.authorWaters, Marken_US
dc.contributor.authorBarbour-Yowell, Sallyen_US
dc.contributor.authorTenhover, Jenniferen_US
dc.contributor.authorLeigh, Howarden_US
dc.author.detailsKimberly Camp, RN, BSN, OCN, Clinical Operations Director, Duke University Hospital, Durham, North Carolina, USA, email: camp0008@mc.duke.edu; Krista Rowe, MSN, CNS, AOCN; Laura Houchin, MSN, CNS, AOCN; Mark Waters, RN, MPH, OCN; Sally Barbour-Yowell, PharmD, BCOP; Jennifer Tenhover, ANP, AOCN; and Howard Leigh, FNP-BCen_US
dc.identifier.urihttp://hdl.handle.net/10755/164933-
dc.description.abstractClinical/Evidence Based Practice: Outpatient chemotherapy has progressed to a combination of targeted and cytotoxic therapies. Increased dermatological toxicities related to targeted therapies spearheaded the development of an algorithm for the management of epidermal growth factor receptor (EGFR) rashes. It is estimated that more than 50% of patients develop a mild to severe rash over the trunk, scalp, face and upper extremities. Skin toxicities can lead to dose reductions and/or dose delays along with decreased quality of life (QOL). Patients may report significant pain and pruritus, anxiety related to body image changes, and socially isolate themselves due to the appearance of the rash. Approximately 32% of providers report discontinuing therapy due to rash. The purpose of this project was to bring together a multidisciplinary group who could develop a clinical algorithm to guide patient care that would assist in minimizing dose delays/reductions and the negative impact on the patient's QOL. A multidisciplinary team was brought together that conducted a literature review and collaborated on the development of a skin toxicity algorithm. Development of the algorithm was accomplished by nurse practitioners, pharmacists and nurses who were identified as key change agents within oncology. A patient educational tool was also developed to compliment the algorithm which reinforces self-care symptom management strategies for good skin health. The algorithm is currently under review by the medical director, division chief, and the pharmacy and therapeutics committee for approval. Once the algorithm has been approved it will be disseminated to the staff in the clinics, infusion center, and pharmacy. Education and implementation of the algorithm and patient education materials is expected by March 2009. Helping patients maintain their QOL by minimizing symptoms and teaching self-care strategies can assist in avoiding delays and dose reductions of recommended cancer therapies. A standardized and consistent regimen for managing skin toxicities will minimize progression and severity of the rash allowing optimal treatment and minimizing the negative cosmetic impact of therapy.en_GB
dc.date.available2011-10-27T12:09:34Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:09:34Z-
dc.conference.date2009en_US
dc.conference.name34th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationSan Antonio, Texas, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.